Researchers at the University of Turku, Finland, have discovered a new biomarker that can predict the progression of multiple ...

Updates in relapsing-remitting MS from AAN 2025 examine neurofilament light protein level as a prognostic biomarker, safety and efficacy of ofatumumab, and benefit of early initiation of ozanimod.

Researchers at the University of Turku, Finland, have discovered a new biomarker that can predict the progression of multiple sclerosis (MS).

The Patient-Centered Outcomes Research Institute (PCORI) gave the Cleveland Clinic $6.7 million to identify optimal RRMS ...

A protein was created where TDP-43 was fused to the SUMO2 protein and these fusion proteins were expressed in cells with or ...